Payment overview · 2025
General Payments
$815.80
8 reported records · 7 companies
Healthcare provider profile · identity verified
Doreen Cherop Karan
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BALA CYNWYD, PA · NPI 1598120693
Verified facts
What the public records show
CMS Open Payments records show Doreen Cherop Karan received $815.80 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Auryxia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $192.02 | 23.5% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $142.21 | 17.4% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $124.80 | 15.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $120.00 | 14.7% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $99.12 | 12.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.69 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.96 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $815.80 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DRIZALMA SPRINKLE Normalized: drizalma sprinkle |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $142.21 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $124.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $123.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $99.12 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $99.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $75.69 | 1 | 2025 |
Source payment records
|
|||||
| FLUARIX QUADRIVALENT Normalized: fluarix quadrivalent |
Biological | GlaxoSmithKline, LLC. | $68.97 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $68.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 18 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 41 |
| Gabapentin | Gabapentin | 208 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 29 |
| Lisinopril | Lisinopril | 152 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 21 |
| Furosemide | Furosemide | 147 | 22 |
| Eliquis | Apixaban | 144 | 15 |
| Sertraline Hcl | Sertraline Hcl | 139 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 20 |
| Omeprazole | Omeprazole | 115 | 15 |
| Montelukast Sodium | Montelukast Sodium | 113 | 11 |
| Losartan Potassium | Losartan Potassium | 112 | 13 |
| Buspirone Hcl | Buspirone Hcl | 107 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 13 |
| Famotidine | Famotidine | 95 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | suppressed |
| Carvedilol | Carvedilol | 88 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 12 |
| Mirtazapine | Mirtazapine | 74 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 11 |
| Metformin Hcl | Metformin Hcl | 70 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 69 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 67 | suppressed |
| Latanoprost | Latanoprost | 67 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 66 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | suppressed |
| Jantoven | Warfarin Sodium | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 57 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Prednisone | Prednisone | 50 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Simvastatin | Simvastatin | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 32 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 17 |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Mirabegron Er | Mirabegron | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Rytary | Carbidopa/Levodopa | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Erythromycin | Erythromycin Base | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Restasis Multidose | Cyclosporine | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Auryxia | Ferric Citrate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Xiidra | Lifitegrast | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Ilevro | Nepafenac | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Xhance | Fluticasone Propionate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $815.80 · 8 records | GlaxoSmithKline, LLC. | AREXVY, DRIZALMA SPRINKLE, FLUARIX QUADRIVALENT, JARDIANCE, NUCALA, Natroba, Ozempic, Spinosad, Vafseo, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error